WO2001055172A3 - COMPLEXE ISOLE COMPRENANT UNE PROTEINE NNT-1 ET EN OUTRE AU MOINS UNE PROTEINE CLF-1 ET/OU UNE PROTEINE sCNTFR$g(a) - Google Patents

COMPLEXE ISOLE COMPRENANT UNE PROTEINE NNT-1 ET EN OUTRE AU MOINS UNE PROTEINE CLF-1 ET/OU UNE PROTEINE sCNTFR$g(a) Download PDF

Info

Publication number
WO2001055172A3
WO2001055172A3 PCT/FR2001/000253 FR0100253W WO0155172A3 WO 2001055172 A3 WO2001055172 A3 WO 2001055172A3 FR 0100253 W FR0100253 W FR 0100253W WO 0155172 A3 WO0155172 A3 WO 0155172A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
scntfrα
nnt
clf
addition
Prior art date
Application number
PCT/FR2001/000253
Other languages
English (en)
Other versions
WO2001055172A2 (fr
Inventor
Greg Elson
Jean-Francois Gauchat
Helene Plun-Favreau
Sylvie Chevalier
Hugues Gascan
Original Assignee
Pf Medicament
Inst Nat Sante Rech Med
Greg Elson
Gauchat Jean Francois
Plun Favreau Helene
Sylvie Chevalier
Hugues Gascan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0001035A external-priority patent/FR2804434A1/fr
Application filed by Pf Medicament, Inst Nat Sante Rech Med, Greg Elson, Gauchat Jean Francois, Plun Favreau Helene, Sylvie Chevalier, Hugues Gascan filed Critical Pf Medicament
Priority to AU2001231917A priority Critical patent/AU2001231917A1/en
Publication of WO2001055172A2 publication Critical patent/WO2001055172A2/fr
Publication of WO2001055172A3 publication Critical patent/WO2001055172A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention a pour objet un nouveau complexe isolé comprenant une protéine NNT-1 et en outre au moins une protéine CLF-1 et/ou une protéine sCNTFRα ainsi que des anticorps dirigés spécifiquement contre ledit complexe. L'invention comprend également une composition comprenant ledit complexe comme médicament pour la prévention et/ou le traitement de maladies neurodégénératives telles que la sclérose latérale amyotrophique, la maladie de Parkinson ou la maladie du Huntington, pour la maintenance de la masse musculaire chez les paralysés, pour le traitement de l'obésité ou du cancer.
PCT/FR2001/000253 2000-01-27 2001-01-26 COMPLEXE ISOLE COMPRENANT UNE PROTEINE NNT-1 ET EN OUTRE AU MOINS UNE PROTEINE CLF-1 ET/OU UNE PROTEINE sCNTFR$g(a) WO2001055172A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001231917A AU2001231917A1 (en) 2000-01-27 2001-01-26 Isolated complex comprising a nnt-1 protein and in addition at least a clf-1 protein and/or a scntfralpha protein

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR00/01035 2000-01-27
FR0001035A FR2804434A1 (fr) 2000-01-27 2000-01-27 Heterocomplexe nnt-1/clf-1 et son utilisation en tant qu'activateur du recepteur complexe cntrfalpha/gp130/lifrbet a
FR0013089A FR2804435A1 (fr) 2000-01-27 2000-10-12 COMPLEXE ISOLE COMPRENANT UNE PROTEINE NNT-1 ET EN OUTRE AU MOINS UNE PROTEINE CLF-1 ET/OU UNE PROTEINE sCNTFRalpha
FR00/13089 2000-10-12

Publications (2)

Publication Number Publication Date
WO2001055172A2 WO2001055172A2 (fr) 2001-08-02
WO2001055172A3 true WO2001055172A3 (fr) 2001-11-15

Family

ID=26212128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/000253 WO2001055172A2 (fr) 2000-01-27 2001-01-26 COMPLEXE ISOLE COMPRENANT UNE PROTEINE NNT-1 ET EN OUTRE AU MOINS UNE PROTEINE CLF-1 ET/OU UNE PROTEINE sCNTFR$g(a)

Country Status (3)

Country Link
AU (1) AU2001231917A1 (fr)
FR (1) FR2804435A1 (fr)
WO (1) WO2001055172A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1159299B1 (fr) * 1999-03-11 2009-01-14 Schering Corporation Cytokines de mammifere : reactifs et procedes associes
EP3436078B1 (fr) * 2016-03-31 2021-10-27 University of Cincinnati Méthodes et compositions pour le traitement de la sla
US20200297868A1 (en) * 2016-12-14 2020-09-24 University Of Cincinnati Methods and compositions for the treatment of als

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033922A1 (fr) * 1997-02-03 1998-08-06 Amgen Inc. Facteur neurotrophique nnt-1
WO1999000415A1 (fr) * 1997-06-30 1999-01-07 Human Genome Sciences, Inc. Cytokine de type cardiotrophine
WO1999035264A1 (fr) * 1998-01-09 1999-07-15 Immunex Corporation Adn codant h14, et polypeptides h14
WO1999040195A1 (fr) * 1998-02-06 1999-08-12 Schering Corporation Proteines de recepteurs de mammiferes; reactifs et procedes apparentes
WO2000053631A1 (fr) * 1999-03-11 2000-09-14 Schering Corporation Cytokines de mammifere : reactifs et procedes associes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033922A1 (fr) * 1997-02-03 1998-08-06 Amgen Inc. Facteur neurotrophique nnt-1
WO1999000415A1 (fr) * 1997-06-30 1999-01-07 Human Genome Sciences, Inc. Cytokine de type cardiotrophine
WO1999035264A1 (fr) * 1998-01-09 1999-07-15 Immunex Corporation Adn codant h14, et polypeptides h14
WO1999040195A1 (fr) * 1998-02-06 1999-08-12 Schering Corporation Proteines de recepteurs de mammiferes; reactifs et procedes apparentes
WO2000053631A1 (fr) * 1999-03-11 2000-09-14 Schering Corporation Cytokines de mammifere : reactifs et procedes associes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALEXANDER W S ET AL: "Suckling defect in mice lacking the soluble haemopoietin receptor NR6.", CURRENT BIOLOGY, vol. 9, no. 11, 3 June 1999 (1999-06-03), pages 605 - 608, XP002155604, ISSN: 0960-9822 *
ELSON GREG C A ET AL: "CLF associates with CLC to form a functional heteromeric ligand for the CNTF receptor complex.", NATURE NEUROSCIENCE, vol. 3, no. 9, September 2000 (2000-09-01), pages 867 - 872, XP001015418, ISSN: 1097-6256 *
GREG C A ELSON ET AL: "CYTOKINE-LIKE FACTOR-1, A NOVEL SOLUBLE PROTEIN, SHARES HOMOLOGY WITH MEMBERS OF THE CYTOKINE TYPE I RECEPTOR FAMILY", JOURNAL OF IMMUNOLOGY,US,THE WILLIAMS AND WILKINS CO. BALTIMORE, vol. 161, 1 August 1998 (1998-08-01), pages 1371 - 1379, XP002111421, ISSN: 0022-1767 *
SENALDI GIORGIO ET AL: "Novel neurotrophin-1/B cell-stimulating factor-3: A cytokine of the IL-6 family", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES,US,NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, vol. 96, no. 20, September 1999 (1999-09-01), pages 11458 - 11463, XP002144214, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU2001231917A1 (en) 2001-08-07
WO2001055172A2 (fr) 2001-08-02
FR2804435A1 (fr) 2001-08-03

Similar Documents

Publication Publication Date Title
WO2003016467A3 (fr) Utilisation d'anticorps ayant une forte affinite pour le peptide a$g(b) dans le traitement de pathologies et de maladies liees a a$g(b)
AU2001233299A1 (en) Methods for treating alzheimer's disease
WO2004005326A3 (fr) Conjugues de tubulysine
AP2004003026A0 (en) Methods for treating ocular neovascular diseases.
EP1765388B8 (fr) Therapie combinee pour la prevention ou le traitement de la maladie d'alzheimer, et kit correspondant
WO2001014424A3 (fr) Anticorps contre l'antigene ctla-4 humain et utilisation
WO2004074232A8 (fr) Derives d'acide 1-phenylalcane-carboxylique pour le traitement de maladies neurodegeneratives
AU2001278084A1 (en) Model for alzheimer's disease and other neurodegenerative diseases
WO2000059946A8 (fr) Hydroxymatairesinol en prevention anti-cancereuse
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
WO2002077172A3 (fr) Methodes servant a inhiber l'angiogenese, la croissance tumorale et la metastase faisant appel a un anti-il8 et a un anti-muc18 entierement humains dans divers types de tumeurs
AU2002239765A1 (en) Antibody pti-hs7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
WO2002074251A3 (fr) Traitement par anticorps monoclonal du cancer du pancreas
AU2003277280A1 (en) Biphenyls and fluorenes as imaging agents in alzheimer's disease
WO2003020963A3 (fr) Proteines impliquees dans le diabete de type 2
WO2003015780A3 (fr) Isoxazolopyridinones
WO2001055172A3 (fr) COMPLEXE ISOLE COMPRENANT UNE PROTEINE NNT-1 ET EN OUTRE AU MOINS UNE PROTEINE CLF-1 ET/OU UNE PROTEINE sCNTFR$g(a)
WO2001007479A3 (fr) Matieres vivantes et methodes utiles pour le diagnostic ou le traitement de maladies
AU2001248760A1 (en) Preventives/remedies for alzheimer's disease
WO2003097082A3 (fr) Traitement de la maladie de crohn ou du psoriasis a partir d'anticorps anti-interferon gamma
WO2003080800A3 (fr) Prevention et traitement de maladies au moyen d'angiogenese et/ou d'antigenes tumoraux
WO2001055219A3 (fr) PROTEINE DE FUSION scsCNTFR/NNT-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CN JP MX US ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CN JP MX US ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP